| Abstrakt: |
A recent study conducted at Odense University Hospital in Denmark explored the expression of Bruton's tyrosine kinase (BTK) in different types of brain lesions in multiple sclerosis (MS) patients. BTK inhibitors (BTKi) are emerging as a potential therapy for MS, as they can cross the blood-brain barrier and modulate B cells and microglia, which play a significant role in active and chronic active lesions. The study found that BTK expression was significantly increased in active and chronic active lesions, particularly in microglia. This suggests that BTKi may have an effect on B cells and microglia/macrophages in active lesions and limit microglia activation in chronic active lesions, potentially reducing tissue damage. [Extracted from the article] |
